CritiTech announces new CEO
This article was originally published in Scrip
CritiTech, a US company conducting R&D into the production and application of fine-particle compounds, has named Dr David Johnston CEO. Dr Johnston most recently served as interim president and CEO for AerovectRX, a spin out from the US Center for Disease Control. Before that, he was senior vice-president of R&D at Nektar Therapeutics.